Xeris Biopharma Holdings Q3 2026 Results: Net Income $11.3M, Up 1718.0% YoY
Xeris Biopharma reported a significant increase in total revenue to $107.2 million for the third quarter of 2026, up from $74.4 million in the prior year. While the company achieved a net income of $11.3 million for the quarter, it recorded a net loss of $17.6 million for the nine-month period, largely driven by a $30.8 million loss on debt extinguishment.
- Key figure
- Net income $11.3M · +1718.0% YoY